Altaris Bets $375M on Drug Modeling Software in Simulations Plus Deal

Altaris Capital Partners is acquiring Simulations Plus, a pharmaceutical simulation software provider, for approximately $375 million in an all-cash transaction that will take the 28-year-old company private. The deal, announced June 16, values Simulations Plus at $61.00 per share — a 31% premium over its closing price the day before announcement and roughly 6x its trailing twelve-month revenue of around $62 million.

The acquisition marks one of the larger software exits in the fragmented pharmaceutical R&D technology sector this year, and it's a clear signal that healthcare-focused private equity firms see value in the picks-and-shovels businesses that power drug development — even as broader biotech valuations remain choppy. Simulations Plus has been publicly traded on Nasdaq since 2006, but its stock has traded in a relatively narrow range over the past two years despite consistent revenue growth in the high single digits.

What makes this deal interesting isn't just the price. It's what Altaris is buying: a company that sells software to predict how drugs behave in the human body before they ever enter clinical trials. That's becoming more valuable as pharmaceutical companies face mounting pressure to reduce the cost and time of bringing new therapies to market. The global drug development process costs an average of $2.6 billion per approved drug, according to recent estimates, and nearly 90% of candidates fail somewhere between Phase I trials and FDA approval. Software that can weed out failures earlier — or optimize formulations before human testing — is worth paying for.

Simulations Plus doesn't make drugs. It makes the modeling tools that help pharma and biotech companies decide which drugs are worth making. Its flagship product, GastroPlus, simulates how oral drugs are absorbed and metabolized. Other tools in its portfolio predict drug-drug interactions, toxicity, and pharmacokinetics across different patient populations. The company's customers include nearly every major pharmaceutical company, from Pfizer and Merck to smaller biotech startups working on early-stage pipelines.

Altaris didn't just buy growth. It bought recurring revenue and customer lock-in. Simulations Plus operates on a subscription model, with most revenue coming from multi-year software licensing agreements and recurring maintenance contracts. That gives the business the kind of predictable cash flow profile that private equity firms prize — especially in a healthcare services portfolio where other assets might be more exposed to reimbursement risk or regulatory volatility.

The company reported approximately $62 million in revenue for its most recent fiscal year, up from roughly $58 million the prior year. Gross margins hover around 75%, typical for enterprise software businesses with low marginal costs. EBITDA margins are estimated in the mid-20% range, though the company has historically reinvested heavily in R&D to expand its simulation capabilities and add modules for biologics, gene therapies, and other next-generation modalities.

Altaris, which manages approximately $4 billion in assets and focuses exclusively on healthcare, has a track record of buying niche service and technology businesses that serve pharmaceutical and medical device companies. Prior investments include contract research organizations, specialty distributors, and healthcare IT firms. The thesis is consistent: find businesses with defensible market positions, high switching costs, and exposure to long-term pharmaceutical R&D spend, then operate them for improved margins and add-on acquisitions.

In this case, Simulations Plus fits the pattern. The company has been around since 1996, giving it deep relationships with Big Pharma R&D teams and a reputation for regulatory credibility — its models are cited in FDA submissions and peer-reviewed publications. Competitors exist, but the market for physiologically based pharmacokinetic (PBPK) modeling software is fragmented, with no single dominant player controlling more than 30% share. That fragmentation creates consolidation opportunities, and Altaris has publicly stated in past deals that it views roll-up strategies favorably when the market structure supports it.

The Simulations Plus acquisition comes at a moment when pharmaceutical R&D is undergoing a structural shift. Clinical trial costs are rising — patient recruitment is harder, regulatory requirements are more stringent, and the complexity of new drug modalities (cell therapies, RNA-based treatments, personalized medicine) is increasing. At the same time, investors and boards are demanding faster time to market and better success rates.

Enter simulation software. The promise is simple: model the biology in silico before running expensive in vivo studies. If a formulation is likely to have poor oral bioavailability or cause liver toxicity in a subset of patients, the software should flag it before the company spends $50 million on a Phase II trial. The technology isn't new — PBPK modeling has been used in drug development for over two decades — but adoption is accelerating as computational power improves and regulatory agencies increasingly accept modeling data as supporting evidence in submissions.

The FDA issued guidance in 2018 encouraging the use of physiologically based pharmacokinetic models to support certain regulatory decisions, and the European Medicines Agency has published similar recommendations. That regulatory tailwind matters. Pharma companies are more willing to invest in simulation tools when they know the output will be viewed as credible by the agencies that ultimately approve or reject their drugs.

Simulations Plus has capitalized on that trend by expanding its platform beyond traditional small-molecule drugs. Recent product development has focused on biologics, including monoclonal antibodies and antibody-drug conjugates, which behave very differently in the body than conventional pills. The company has also invested in machine learning capabilities to improve predictive accuracy, though it has been careful not to oversell AI as a magic bullet — a wise move given the skepticism many pharmaceutical scientists still harbor toward black-box algorithms in safety-critical applications.

The valuation — roughly 6x trailing revenue — sits in the middle of the range for specialized enterprise software companies serving life sciences. It's not cheap, but it's not egregious either, particularly given the recurring revenue profile and the regulatory moat. Comparable recent transactions in pharma tech have ranged from 4x to 8x revenue depending on growth rates and competitive positioning.

The 31% premium over the prior day's close is notable but not extraordinary in the context of take-private deals. What it does signal, though, is that Simulations Plus was likely undervalued by public markets relative to what a strategic buyer or financial sponsor was willing to pay. The stock had been trading largely sideways for two years despite revenue growth, suggesting that investors either didn't appreciate the recurring revenue model or were frustrated by the company's relatively modest scale and limited investor relations presence.

Simulations Plus brings more to the table than just a product portfolio. It has a services arm — Cognigen, a pharmacometrics consulting division — that provides hands-on modeling and simulation support to pharmaceutical clients who either lack in-house expertise or need outside validation for regulatory submissions. This consulting business is higher-touch and less scalable than software, but it deepens customer relationships and creates opportunities for upselling software licenses.

The company also owns DILIsym Services, which focuses on simulating drug-induced liver injury — one of the leading causes of drug withdrawals and black-box warnings. Liver toxicity is notoriously hard to predict in preclinical testing, and DILIsym's quantitative systems pharmacology models are used by both pharma companies and the FDA itself in safety assessments. That gives Simulations Plus credibility in one of the highest-stakes areas of drug development.

Then there's the IP. Simulations Plus holds patents and proprietary algorithms covering aspects of drug absorption, distribution, metabolism, and excretion (ADME) modeling. While software patents are notoriously difficult to enforce and the competitive moat in enterprise software usually comes from customer switching costs rather than legal barriers, the IP does provide some level of differentiation — especially in specialized areas like pediatric dosing or drug-drug interaction prediction where the company has published extensively.

For Altaris, the acquisition also offers a platform for add-on deals. The pharmaceutical software and services market is highly fragmented, with dozens of smaller players focused on narrow niches — clinical trial design, regulatory document management, biostatistics, real-world evidence analytics. Simulations Plus could serve as an anchor asset in a broader rollup strategy, though Altaris has not publicly disclosed whether that's part of the plan.

What's clear is that Altaris sees an opportunity to operate the business with more focus and potentially higher margins than it achieved as a small-cap public company. Public market scrutiny and quarterly reporting requirements don't always align well with long R&D cycles and lumpy enterprise sales, both of which characterize Simulations Plus's business model. Private ownership could allow for more patient capital allocation and fewer short-term performance pressures.

No deal is without risk, and this one has a few worth watching. First, customer concentration. While Simulations Plus serves hundreds of clients, a meaningful portion of revenue likely comes from a small number of large pharmaceutical companies. If one or two major customers decide to build in-house modeling capabilities or switch to a competitor, that could hurt growth. The company hasn't disclosed detailed customer concentration metrics in recent filings, but it's a standard risk in enterprise software serving a consolidated buyer base.

Second, the pace of scientific change. Drug development is moving toward modalities — gene editing, mRNA therapies, cell-based treatments — that behave very differently from traditional small molecules. Simulations Plus has invested in expanding its models to cover biologics and advanced therapies, but it's not yet clear whether its platform will remain the gold standard as the industry shifts further toward personalized medicine and away from one-size-fits-all oral drugs. If the company's models don't keep pace with the science, customers will go elsewhere.

The transaction is structured as an all-cash merger, with Altaris acquiring 100% of Simulations Plus's outstanding shares at $61.00 per share. The deal has been approved by the company's board of directors and is expected to close in the fourth quarter of 2026, subject to shareholder approval and customary regulatory clearances. No financing contingency has been disclosed, suggesting Altaris has already secured committed capital — likely a mix of fund equity and debt financing, though the exact capital structure hasn't been made public.

Simulations Plus's management team, including CEO Shawn O'Connor, is expected to remain in place post-acquisition. That's standard in software buyouts where continuity matters — customer relationships and product roadmaps are typically driven by the existing leadership, and replacing them mid-flight creates risk. Altaris will install its own board and likely bring in operational partners to focus on scaling sales, improving margins, and potentially pursuing add-on acquisitions.

Goldman Sachs is serving as financial advisor to Simulations Plus, and Latham & Watkins is providing legal counsel. Altaris is being advised by Kirkland & Ellis on legal matters. The presence of top-tier advisors on both sides suggests the deal was competitive and that Simulations Plus's board ran a process to evaluate alternatives before agreeing to the Altaris offer.

One question left unanswered in the announcement: were there other bidders? A 31% premium suggests some level of negotiation, and it's plausible that other healthcare-focused PE firms or strategic buyers in the pharma services space kicked the tires. Simulations Plus's relatively small size — $375 million enterprise value — puts it within reach of a wide range of financial and strategic acquirers, and the recurring revenue model makes it attractive as a bolt-on to larger healthcare IT or CRO platforms.

The Simulations Plus deal is the latest in a series of private equity acquisitions targeting specialized software and services businesses that serve pharmaceutical R&D. Over the past 18 months, PE firms have acquired contract research organizations, clinical trial management platforms, regulatory consulting firms, and data analytics providers — all betting on the same underlying thesis: pharmaceutical companies are outsourcing more of their R&D infrastructure, and the vendors that provide that infrastructure are attractive, capital-light, high-margin businesses.

What makes pharma software appealing to financial buyers is the combination of recurring revenue, long customer relationships, and exposure to a secular growth driver — global pharmaceutical R&D spending, which has grown at a compound annual rate of roughly 3-5% over the past decade and shows no signs of slowing. Even as biotech funding cycles ebb and flow, Big Pharma continues to invest heavily in pipeline development, and much of that spend goes to the picks-and-shovels providers like Simulations Plus.

The risk, of course, is that the market becomes overcrowded with financial buyers chasing the same assets, driving up valuations and making it harder to generate strong returns. The 6x revenue multiple Altaris is paying for Simulations Plus is reasonable but not cheap — it implies that the firm is banking on some combination of revenue growth acceleration, margin expansion, or multiple arbitrage via add-on acquisitions to hit its return targets.

One thing to watch: whether Altaris uses Simulations Plus as a platform for consolidation. If the firm starts acquiring smaller pharmacometrics consultancies, clinical pharmacology software providers, or toxicology modeling specialists and rolling them into Simulations Plus, that would signal a broader thesis about building a one-stop shop for pharmaceutical modeling and simulation. That's a plausible strategy — many pharma companies would prefer to work with a single vendor for related services rather than managing relationships with five different niche providers — but execution is hard, especially when integrating scientific software with different codebases and customer workflows.

For existing shareholders, the deal offers a clean exit at a meaningful premium. Anyone who bought in the past year is likely walking away with a solid gain — the stock traded as low as $42 per share in mid-2025 before climbing into the high $40s in early 2026. The $61 offer represents a roughly 45% gain from those lows. Long-term holders who rode the stock through its public market years may have mixed feelings — the company has been a steady grower but never a high-flyer, and some shareholders might have preferred to see it remain independent and keep compounding.

The shareholder vote, expected in the coming months, is likely a formality. The board has unanimously recommended the deal, and the premium is large enough that it's hard to imagine a scenario where shareholders reject it unless a competing bidder emerges. No such bidder has been disclosed, and the announcement doesn't mention a go-shop period, suggesting that the company's board is confident this is the best available offer.

Step back from the specifics of this deal, and a pattern emerges. Private equity firms — especially those with healthcare mandates like Altaris — are increasingly focused on what you might call "healthcare infrastructure" businesses. Not the hospitals or insurance companies that dominate headlines, but the behind-the-scenes service providers, software platforms, and specialized consultancies that make the system run. Contract research organizations. Revenue cycle management software. Medical device testing labs. Pharmacy benefit management platforms. And now, pharmaceutical simulation software.

The appeal is obvious: these businesses tend to have high margins, low capital intensity, and exposure to long-term secular trends (aging populations, rising healthcare spending, increasing regulatory complexity) that drive demand regardless of economic cycles. They're also often overlooked by public markets, which tend to favor faster-growing, higher-profile companies. That creates an opportunity for financial buyers to acquire assets at reasonable valuations, operate them for improved profitability, and either flip them to strategics or hold them for long-term cash generation.

Simulations Plus fits this profile perfectly. It's not a household name. It doesn't have the growth trajectory of a hot biotech or the scale of a mega-cap pharma company. But it has a defensible market position, a loyal customer base, and a business model that throws off consistent cash. For a healthcare-focused PE firm like Altaris, that's exactly what you want.

Whether this deal ultimately delivers strong returns for Altaris will depend on execution — how well the firm can grow revenue, expand margins, and potentially build a larger platform through add-ons. But the thesis is sound, and the market opportunity is real. Pharmaceutical companies aren't going to stop needing simulation software anytime soon. If anything, they're going to need more of it as drug development gets more complex and expensive. That's a tailwind Altaris can work with.

The Simulations Plus deal is expected to close in Q4 2026, assuming shareholders approve and regulatory clearances come through without hiccups. In the meantime, a few things are worth monitoring. First, whether any competing bids emerge. The announcement doesn't preclude the possibility, and if a strategic buyer — say, a larger healthcare IT company or a pharma services conglomerate — decides Simulations Plus is a strategic fit, they could come over the top with a higher offer.

Second, watch for signs of how Altaris plans to operate the business post-close. Will they invest aggressively in sales and marketing to accelerate growth? Will they pursue add-on acquisitions to build a broader platform? Or will they focus on margin expansion and cash generation, running the business for steady EBITDA and positioning it for a sale to a strategic in 3-5 years? The firm's past deals suggest they're capable of all three, but the specific playbook here will become clearer once the transaction closes.

Finally, keep an eye on the broader pharma software M&A market. If this deal goes smoothly and Altaris generates strong returns, expect other PE firms to take notice. The market for specialized pharmaceutical R&D tools is still fragmented enough that there are plenty of other potential targets, and the same dynamics that made Simulations Plus attractive — recurring revenue, customer lock-in, exposure to pharmaceutical R&D spend — apply to dozens of other companies in adjacent niches.

For now, though, the story is straightforward: a healthcare-focused private equity firm saw value in a quietly profitable software business that public markets had overlooked, paid a fair premium to take it private, and is betting that it can operate the business more effectively without the constraints of quarterly earnings calls and activist investors. Whether that bet pays off will take years to know. But the logic behind it is hard to argue with.